Cognyte Software Ltd. (CGNT:NASDAQ) closed at $9.76 on October 23, 2026, up 5.23% on the day. The stock trades 20.7% below its 52-week high of $12.31 and 55.2% above its 52-week low of $6.29. Over the past year, it gained 16.5%. Cognyte Software Ltd. is part of the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus).
In 252 trading sessions since October 23, 2025, CGNT closed higher on 129 days (51%). Its best day was May 29, 2026 (+9.88%) and its worst was June 3, 2026 (-20.57%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets products for the urology market and flexible endoscopy. The company principally offers Urgent PC neuromodulation system for the overactive bladder and associated symptoms of urge incontinence, urinary urgency and urinary frequency; and Macroplastique implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. It also provides EndoSheath system, which combines endoscopic technology with a sterile and disposable microbial barrier for flexible endoscopy. In addition, the company offers Macroplastique products for treatment of vesicoureteral reflux; PTQ Implants, which provide a minimally-invasive, soft-textured permanent implant for treatment of fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants, a silicone elastomer bulking material for vocal cord rehabilitation applications, as well as distributes wound care products. The company sells its products primarily to urologists, urogynecologists, and gynecologists through a direct sales organization in the...
Find more stocks like CGNT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.